Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / IGF-1 LR3

IGF-1 LR3

IGF-1 LR3 (Long R3 IGF-1): how it differs from the approved drug mecasermin, its FDA status, missing human data, risks and sport ban.

Not approved for humans · Evidence grade D · Reviewed

Not approved by the FDA for human use. Not for human consumption. This page describes IGF-1 LR3 only to explain its regulatory status, what has been studied and its known risks. Drawline does not recommend obtaining or using it. Disclaimer

Approved and studied uses
  • Not approvedMuscle growthNot approved; no human trials
Training and drug testingBanned at all times

WADA bans IGF-1 and its analogues at all times under class S2 (peptide hormones, growth factors and related substances).

Drug-tested athletes can look up any substance on Global DRO, run by national anti-doping agencies. Supplements can contain banned substances that are not on the label. Drawline does not suggest when to train or inject.

IGF-1 LR3 (Long R3 IGF-1, LR3 IGF-I). Insulin-like growth factor analog.

DNot approved for humans. Evidence grade D: animal and lab data only.

What is IGF-1 LR3?

IGF-1 LR3 is a lab-made version of insulin-like growth factor 1 (IGF-1) with 83 amino acids instead of 70: an arginine replaces glutamic acid at position 3, and 13 extra amino acids are added at the front. The changes make it bind weakly to the proteins that normally hold IGF-1 in check, so it stays active longer. It was made as a cell culture reagent.

Is IGF-1 LR3 FDA-approved?

No IGF-1 LR3 product is approved by FDA for any human use. The only approved IGF-1 drug in the United States is mecasermin (Increlex), approved in 2005 for growth failure in children with severe primary IGF-1 deficiency. Mecasermin has the natural human sequence and is a different molecule, so its approval does not cover IGF-1 LR3.

What does the evidence show for IGF-1 LR3?

No published human trials of IGF-1 LR3. Its data come from cell culture and animal studies that compared it with natural IGF-1.

What are the known risks of IGF-1 LR3?

Its safety in people has not been studied. The label of the approved IGF-1 drug, mecasermin, warns of low blood sugar, raised pressure inside the skull, enlarged tonsils and adenoids, hip growth-plate slips in children and cancers seen in treated children. IGF-1 LR3 is built to stay active longer than natural IGF-1, and how that changes these risks is unknown. Sport: WADA bans IGF-1 and its analogues at all times under class S2 (peptide hormones, growth factors and related substances).

How is IGF-1 LR3 measured?

A powder vial: enter the amount in the vial and the water added, and the calculator shows the syringe units for a prescribed dose. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.

Sources: FDA label: Increlex (mecasermin) injection, 2025; FDA label: Increlex (mecasermin), 2023, malignant neoplasia warning; Francis et al., IGF-I fusion analogues and binding protein affinity, J Mol Endocrinol (1992); WADA: 2026 Prohibited List. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.